Genetics: Predictive value of KRAS mutations in chemoresistant CRC

Nat Rev Clin Oncol. 2009 Jun;6(6):306-7. doi: 10.1038/nrclinonc.2009.69.

Abstract

On the basis of the results of KRAS analysis from the CO.17 randomized, controlled, phase III study by Karapetis et al., KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.

Publication types

  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Colorectal Neoplasms / diagnosis
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / genetics*
  • Drug Resistance, Neoplasm*
  • Humans
  • Mutation / genetics*
  • Prognosis
  • Proto-Oncogene Proteins / genetics*
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins / genetics*

Substances

  • Antineoplastic Agents
  • KRAS protein, human
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins